Skip to main content
Toggle navigation
Login
Search
Home
Tweets by ASCPT 2023 Annual Meeting
Oncology (ONC)
Home
Oncology (ONC)
Oncology (ONC)
Type here to filter the list
EP-005 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB.
Favorite
EP-006 - AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF COADMINISTRATION OF SOTORASIB ON THE PHARMACOKINETICS OF ROSUVASTATIN, A BREAST CANCER RESISTANCE PROTEIN SUBSTRATE, IN HEALTHY SUBJECTS.
Favorite
EP-007 - CENTRAL ADMINISTRATION OF COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT PEPTIDE REDUCES CISPLATIN-INDUCED EMESIS AND C-FOS EXPRESSION IN SUNCUS MURINUS.
Favorite
EP-008 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TREMELIMUMAB 300 MG SINGLE DOSE COMBINED WITH DURVALUMAB 1500 MG EVERY 4 WEEKS (STRIDE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA.
Favorite
PI-010 - A DDI STUDY TO EVALUATE THE EFFECT OF MULTIPLE ORAL ADMINISTRATION OF RIFAMPICIN ON THE PHARMACOKINETICS OF VALEMETOSTAT IN HEALTHY PARTICIPANTS.
Favorite
PI-011 - CHARACTERIZING THE RELATIONSHIP BETWEEN CELLULAR KINETICS AND RESPONSE TO SUPPORT DOSING RECOMMENDATIONS FOR CD19-TARGETED 19(T2)28Z1XX CELL THERAPY.
Favorite
PI-012 - CLINICAL EFFICACY OF CAR-T AND CAR-NK FOR THE TREATMENT OF HEMATOLOGIC AND SOLID TUMOR MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Favorite
PI-013 - COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB + BINIMETINIB.
Favorite
PI-014 - DETERMINATION OF ABSOLUTE BIOAVAILABILITY OF QUIZARTINIB USING A MICROTRACER.
Favorite
PI-015 - DEVELOPMENT OF USER-FRIENDLY BAYESIAN PREDICTIVE PLATFORM FOR BLOOD BORON-10 PHARMACOKINETICS FOLLOWING INTRAVENOUS INFUSION OF [10B]L-4-BORONOPHENYLALANINE.
Favorite
PI-016 - EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS.
Favorite
PI-017 - ELIGIBILITY CRITERIA OF EARLY PHASE ONCOLOGY TRIALS.
Favorite
PI-018 - FIRST-IN-HUMAN (FIH) HEALTHY VOLUNTEER (HV) STUDIES FOR ONCOLOGY THERAPEUTICS: A FRAMEWORK OF APPLICATION IN EARLY ONCOLOGY CLINICAL DEVELOPMENT.
Favorite
PI-019 - IDENTIFICATION OF S100A9 AS A THERAPEUTIC TARGET IN PACLITAXEL-INDUCED PERIPHERIAL NEUROPATHY (PIPN).
Favorite
PI-020 - IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC).
Favorite
PI-100 - THE DRUG-DRUG INTERACTION (DDI) EFFECT OF STEADY STATE ITRACONAZOLE EXPOSURE ON SINGLE DOSE PHARMACOKINETICS (PK) OF LAZERTINIB.
Favorite
PII-034 - INVESTIGATION OF DRUG COMBINATIONS IN CANCER THROUGH UNBIASED IDENTIFICATION OF RECURRING DRUG RESPONSE PATTERNS IN CELL LINES.
Favorite
PII-035 - MACHINE LEARNING-BASED DOSE OPTIMIZATION DESIGN INCORPORATING EXPOSURE-RESPONSE RELATIONSHIP IN CELL THERAPY.
Favorite
PII-036 - MASS BALANCE AND METABOLITE IDENTIFICATION OF VALEMETOSTAT AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY MALE SUBJECTS.
Favorite
PII-037 - MTD IN DRUG COMBO: AN EXPERT CURATED MTD DATA SET FOR EFFICIENT DRUG COMBINATION PHASE 1 TRIAL DESIGN.
Favorite
PII-038 - MULTICENTER PHARMACOKINETIC STUDY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER IN OLDER ADULTS AGED OVER 75 YEARS.
Favorite
PII-039 - PHARMACOKINETICS OF INTESTINAL P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE WITH AND WITHOUT CONCOMITANT QUIZARTINIB.
Favorite
PII-040 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING OF VALEMETOSTAT TO INFORM DOSE RECOMMENDATIONS WHEN CO-ADMINISTERED WITH CYP3A/P-GP MODULATORS.
Favorite
PII-041 - POTENTIAL STRATEGIES TO OPTIMIZE CAR-T CELL EXPOSURE IN ABSENCE OF DOSE-EXPOSURE RELATIONSHIPS LEVERAGING CELL KINETIC/DYNAMIC MODELS.
Favorite
PII-042 - TRANSLATABILITY OF IN VITRO POTENCY TO CLINICALLY EFFICACIOUS EXPOSURE FOR MOLECULARLY TARGETED SMALL MOLECULE ONCOLOGY DRUGS.
Favorite
PII-043 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Favorite
PII-044 - UNDERSTANDING METHOTREXATE CONCENTRATIONS AND ASSOCIATED TOXICITIES TO GUIDE SUPPORTIVE CARE IN PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL).
Favorite
PII-045 - USE OF A POPULATION PHARMACOKINETIC MODELLING AND SIMULATION APPROACH TO IDENTIFY FLAT DOSES OF DOMVANALIMAB IN PHASE 3 STUDIES.
Favorite
PWII-003 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Favorite
